BioNexus Gene Lab Corp. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
BioNexus Gene Lab Corp. (BGLC) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$543.58 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-05-15
- BioNexus Gene Lab Corp. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$543.58K.
- BioNexus Gene Lab Corp. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$708.99K.
- BioNexus Gene Lab Corp. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$616.17K, a 409.47% decline year-over-year.
- BioNexus Gene Lab Corp. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-03-31 was -$623.33K.
- BioNexus Gene Lab Corp. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$2.98M.
- BioNexus Gene Lab Corp. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$1.60M, a 160.80% decline from fiscal 2023.
- BioNexus Gene Lab Corp. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was $2.63M.
- BioNexus Gene Lab Corp. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$355.97K, a 147.36% decline from fiscal 2021.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-03-31 | -$543.58K 10-Q · filed 2026-05-15 | |||||
| 2025-12-31 | -$2.98M 10-K · filed 2026-04-14 | |||||
| 2025-09-30 | -$708.99K 10-Q · filed 2025-11-14 | -$1.33M derived: sum of 2 quarters · filed 2025-11-14 | -$1.95M derived: sum of 3 quarters · filed 2026-05-15 | -$4.80M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2025-06-30 | -$616.17K 10-Q · filed 2025-11-14 | -$1.24M derived: sum of 2 quarters · filed 2026-05-15 | -$4.09M derived: sum of 3 quarters · filed 2026-05-15 | -$5.43M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2025-03-31 | -$623.33K 10-Q · filed 2026-05-15 | -$3.47M derived: sum of 2 quarters · filed 2026-05-15 | -$4.82M derived: sum of 3 quarters · filed 2026-05-15 | -$4.62M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | -$2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | -$4.19M derived: sum of 2 quarters · filed 2026-04-14 | -$3.99M derived: sum of 3 quarters · filed 2026-04-14 | -$1.60M 10-K · filed 2026-04-14 | $1.60M 10-K · filed 2025-04-15 | |
| 2024-09-30 | -$1.35M 10-Q · filed 2025-11-14 | -$1.15M derived: sum of 2 quarters · filed 2025-11-14 | $1.25M 10-Q · filed 2024-11-15 | -$1.56M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $199.10K 10-Q · filed 2025-11-14 | $95.35K 10-Q · filed 2024-08-14 | -$213.12K derived: sum of 3 quarters · filed 2025-11-14 | $3.05M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-03-31 | -$103.76K 10-Q · filed 2025-11-14 | $103.76K 10-Q · filed 2024-05-15 | -$412.22K derived: sum of 2 quarters · filed 2025-11-14 | $2.85M derived: sum of 3 quarters · filed 2025-11-14 | $2.46M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2023-12-31 | -$308.46K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $2.96M derived: sum of 2 quarters · filed 2025-04-15 | $2.56M derived: sum of 3 quarters · filed 2025-04-15 | $2.63M 10-K · filed 2025-04-15 | -$2.63M 10-K · filed 2024-04-16 | |
| 2023-09-30 | $3.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $2.87M derived: sum of 2 quarters · filed 2024-11-15 | $2.94M 10-Q · filed 2024-11-15 | $2.78M derived: sum of 4 quarters · filed 2024-11-15 | ||
| 2023-06-30 | -$397.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$328.32K 10-Q · filed 2024-08-14 | -$485.29K derived: sum of 3 quarters · filed 2024-08-14 | -$562.69K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $69.07K 10-Q · filed 2024-05-15 | -$87.90K derived: sum of 2 quarters · filed 2024-05-15 | -$165.30K derived: sum of 3 quarters · filed 2024-05-15 | -$303.97K derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | -$156.97K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$234.37K derived: sum of 2 quarters · filed 2024-04-16 | -$373.03K derived: sum of 3 quarters · filed 2024-04-16 | -$355.97K 10-K · filed 2024-04-16 | ||
| 2022-09-30 | -$77.40K 10-Q · filed 2022-11-14 | -$216.06K derived: sum of 2 quarters · filed 2022-11-14 | -$199.00K 10-Q · filed 2022-11-14 | -$143.89K derived: sum of 4 quarters · filed 2023-03-31 | ||
| 2022-06-30 | -$138.66K 10-Q · filed 2022-08-15 | -$121.60K 10-Q · filed 2022-08-15 | -$66.48K derived: sum of 3 quarters · filed 2023-03-31 | $228.84K derived: sum of 4 quarters · filed 2023-03-31 | ||
| 2022-03-31 | -$17.07K 10-Q · filed 2022-05-16 | $72.18K derived: sum of 2 quarters · filed 2023-03-31 | $367.50K derived: sum of 3 quarters · filed 2023-03-31 | $395.76K derived: sum of 4 quarters · filed 2023-03-31 | ||
| 2021-12-31 | $89.24K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $384.56K derived: sum of 2 quarters · filed 2023-03-31 | $412.83K derived: sum of 3 quarters · filed 2023-03-31 | $751.57K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $295.32K 10-Q · filed 2022-11-14 | $323.58K derived: sum of 2 quarters · filed 2022-11-14 | $662.33K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $28.26K 10-Q · filed 2022-08-15 | $367.01K 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | -$338.74K 10-Q · filed 2022-05-16 | |||||
| 2020-12-31 | $1.09M 10-K · filed 2022-04-06 | |||||
| 2020-06-30 | -$35.84K 10-Q · filed 2021-11-15 | -$83.79K derived: sum of 2 quarters · filed 2021-11-15 | ||||
| 2020-03-31 | -$47.95K 10-Q · filed 2020-05-08 | |||||
| 2019-12-31 | -$246.47K 10-K · filed 2021-03-30 | |||||
| 2019-09-30 | -$22.03K 10-Q · filed 2019-11-14 | -$92.43K derived: sum of 2 quarters · filed 2019-11-14 | -$246.32K derived: sum of 3 quarters · filed 2019-11-14 | |||
| 2019-06-30 | -$70.40K 10-Q · filed 2019-11-14 | -$224.29K derived: sum of 2 quarters · filed 2019-11-14 | ||||
| 2019-03-31 | -$153.89K 10-Q · filed 2019-11-14 | -$61.47K 10-Q · filed 2019-05-15 | ||||
| 2018-12-31 | $26.45K 10-K · filed 2020-03-31 | |||||
| 2018-03-31 | $271.86K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |